FEAT DAILY NEWSLETTER
Sacramento, California http://www.feat.org
July 25, 2001 Search
www.feat.org/search/news.asp
Evidence of a Science Bending Rogue Group Within CDC?
Centers for Disease Control and Obfuscation
Commentary by
Teresa Binstock
[Yesterday the FEAT Daily Newsletter reproduced a news
post from the Sunday Times in England who reported on an official study used by
the CDC to claim that there is no vaccine-autism connection—as being
significantly flawed, “New Autism Doubt On Mercury In Vaccines” by Rosie
Waterhouse. http://www.sunday-times.co.uk/news/pages/sti/2001/07/22/stinwenws01001
. The report quotes the study’s author admitting error - error serious enough
to discredit the study and embarrass the CDC.
The following commentary is by Teresa Binstock, a reputable researcher
in the area of Developmental & Behavioral Neuroanatomy. -LS]
As summarized by Rosie Waterhouse’s news item, a
transcript of the CDC’s secret meeting about thimerosal effects indicates that
a small group within the CDC acknowledges major flaws within its initial study
of the autism epidemic’s link to vaccinal ethylmercury.
Despite this awareness, this small but influential group
within the CDC (ie, the group that enacted the fatally flawed “study”) has
touted and continues to use the study’s “conclusions”—eg, on the webpages of
the American Academy of Pediatrics (spring, 2000) and at the recent Institute
of Medicine (IOM) hearing (July 16, 2001).
What the CDC’s secret meeting transcript conveys is that
the study’s data about autism were insufficient.
As a result, conclusions about rates of autism in the
pediatric cohort from several HMOs in the study are fictional.
Yet invalid findings do not stop this CDC group from
continuing to disseminate misleading conclusions.
Importantly, as indicated by reporters’ rhetoric in recent
Boston Globe and Lancet articles about the IOM hearing, a tradition of respect
for the CDC enables the phony conclusions to be presented as if valid.
Paragraphs that follow are an attempt to set forth a
summary of what this “rogue group” within the CDC has achieved and continues to
achieve.
The seriously flawed CDC “study”—initially distributed as
RL Davis et al, spring 2000 -- had at least three major flaws:
A) The HMO data had
major under-reporting of autism;
B) Data analysis by
Davis et al did not include susceptible subgroups likely to be more affected by
injected ethylmercury;
C) Davis et al relied
upon the EPA’s “safe” limit for methylmercury, which had been derived in
relation to gradually ingested mercury and which, therefore, minimized the fact
that during the 1990s human infants and toddlers had been injected with bolus
doses of ethylmercury, which persisted in their bodies during a post-vaccinal,
extended pulse of cytokines, which alter permeability of intestinal tissue and
of the blood-brain barrier.
These several factors—and others identified by analysts,
eg, Thomas Kurt, MD—indicate that the rate of autism “documented” by Davis et
al was an extreme under-representation of the actual rates of autism among
children within the HMOs whose data Davis et al utilized.
Despite these flaws the CDC’s rogue team has continued to
distribute and utilize the flawed data and the misleading conclusions derived.
The CDC’s rogue team has stated and continues to state
that an association with autism was not found.
Note: this statement is inaccurate and is quite different
from what the CDC ought be stating, namely, that the study design was
inadequate for evaluating a link between thimerosal (TMS; 49.6% ethylmercury by
weight) and the increased incidence of autism.
Yet despite the flawed study, the CDC’s team continues to
tout the study’s “conclusions” as if valid, which they are not!
At the IOM hearing (7.16.01), the CDC presented summaries
of its “Phase 1 and Phase 2” studies (ie, several versions of what had been
called RL Davis et al, spring of 2000) as if the Phase 1 and Phase 2 studies
had had valid methodologies and had thereby derived valid conclusions about autism
and thimerosal.
In fact, during the hearing, the CDC appeared content to
convey the impression that conclusions from the Phase 1 and Phase 2 studies were
legitimate. (See The Lancet for
medical-reporter’s rhetoric indicating how well the CDC succeeded in
obfuscating the significance of vaccinal thimerosal).
Furthermore, the CDC’s rogue team and a U of Washington
research group are designing a Phase 3 study wherein a link between autism and
thimerosal will not be explored.
At the IOM hearing, the impression conveyed by the U
Washington presenter was that there was no need to study what had already been
found to be non-existent.
In my opinion, this requires a severe leap of faith.
Even Alice in Wonderland might pause incredulously.
The CDC acknowledges (off the record and in secret
meetings) that the
Phase 1 and Phase 2 Davis et al studies were seriously
flawed in regard to autism, yet the CDC is happy to proceed with a Phase 3
study that omits autism—because, so we were told, there was no finding of an autism/thimerosal
study in the Phase 1 and Phase 2 studies.
In other words, despite the fact that the CDC’s Davis et al
methodology was fatally flawed in regard to autism and thimerosal, the CDC’s rogue
team and their U of Washington allies seem quite willing to continue diverting
attention away from the substantial likelihood that physician-injected
ethylmercury has been an etiologic factor in many cases of autism and related
disorders.
If ADHD, Tourette’s, PDD, and PDD/NOS are added, then the
number of children adversely affected by physician-injected thimerosal is
potentially huge.
At the IOM hearing, presenter Mark Blaxill summarized
epidemiological similarities between autism’s increase and the increased use of
vaccines containing TMS.
He also expressed dismay that the CDC group most
responsible for developing and encouraging TMS-injections into neonates (via
the HepB vaccine) is the group that also has been conducting and superintending
studies intended to evaluate the relationship between autism and injected-ethylmercury.
Given the 1990s history of injecting thimerosal and the
recent history of CDC-led “studies” about thimerosal, the CDC’s conflict of
interest is clear.
The actions by the CDC’s rogue team appear to be masking
and diverting attention away from thimerosal’s adverse effects in hundreds of
thousands of children.
Excerpts from the CDC’s secret meeting—obtain via the
Freedom of Information act—were presented to IOM by representatives of
SafeMinds (http://www.SafeMinds.com).
As an official submission to the hearing, the SafeMinds
letter to IOM is to be posted on the IOM website—as will other materials that
implicate thimerosal injections as having damaged many of America’s children
(and those in other countries too).
Having the CDC team that developed and encouraged early
infant injections with TMS also be running studies about TMS is akin to having
Al Capone investigate the liquour business in 1930s Chicago.
That the CDC’s confict of interest is having a real effect
is seen in five factors:
i) The CDC continues
to trumpet the Phase 1 and Phase 2 conclusions as if valid, which they are not;
ii) The CDC continues
to utilize the EPA’s so-called “safe” limit for ingested organic mercury
despite the fact that vaccinal ethylmercury was injected;
iii) The CDC continues
to perform data analysis while ignoring the fact that some children are more
susceptible to adverse sequelae from bolus exposures to toxic metals;
iv) The CDC is allowing
a major “Phase 3” study to proceed without autism as a focus;
v) The CDC’s rogue
team uses its organization’s prestige as a lever whereby the flawed conclusions
autism/thimerosal conclusions of Davis et al are presented as if acceptable and
useful—eg, in allowing Phase 3 to omit autism.
At the IOM hearing, an autism-parent suggested that the
HMO data utilized by the CDC ought be analyzed by professionals selected by
trusted autism organizations.
Not surprisingly, the CDC’s Dr. Chen—apparently a leading
actor in the development and use of the HepB for neonates and infants—took the microphone
and offered reasons why independent analysis ought not occur.
After the meeting, Beth Clay—assistant to Congressman Dan
Burton— commented that the CDC seems quite ready to allow new “outsiders” to
view the HMO data so long as the CDC selects who those outside experts are.
In my opinion, outside analysis of the CDC’s primary data
for Davis et al ought occur; and the analysts ought be persons not within and
not hand-picked by the CDC.
Furthermore, the CDC’s conflict of interest already has a
track record of diverting attention away from the link between injected
ethylmercury and autism.
A solution is needed to the CDC’s conflict of
interest.
By continuing to misuse Davis et al conclusions—the
CDC’s rogue
team continues to shape public opinion and near-future
research regarding the link between thimerosal and autism.
>> DO SOMETHING ABOUT AUTISM NOW <<
Subscribe, Read, then Forward the FEAT Daily
Newsletter.
To Subscribe go to www.feat.org/FEATnews No Cost!
Lenny Schafer, Editor Catherine Johnson PhD
Ron Sleith Kay Stammers
Editor@feat.org Edward Decelie CALENDAR: Michelle Guppy events@feat.org
Unsubscribe: FEATNews-signoff-request@LIST.FEAT.ORG
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.